Black Friday saleUp to 70% OFF

Astrazeneca

AZN To Test Yearly Pivot Support AstraZeneca marginally eclipsed its prior cycle highs through the 72.00 level before pulling back to suggest a potential weekly double top pattern, however, I would highlight the lack of momentum divergence at this point, which suggests to me that the current retreat is corrective. On the four-hour time frame, we can clearly see an interim 5-wave sequence has been completed, I am now looking for a corrective cycle to unfold that ultimately tests and hold the yearly pivot point at the 64.00 area, from hear I will be looking for bullish reversal patterns to re-engage long exposure to target are retest and break of the prior cycle highs through 72.00 to challenge the weekly projected trend channel support towards the 76.00 level. A loss of the yearly pivot support on a daily closing basis would suggest a deeper correction is likely to unfold opening a test of the weekly high-volume node and projected trend channel support at the 55/56.00 area.
NASDAQ:AZN
by Tickmill
ARDS first Investor call of 2022. Phase 3 news ???Aridis Pharmaceuticals announced first Investor call of 2022 for today, after the closing bell. Exiting pipeline with 2 phase 3 drugs and their monoclonal antibody cocktail. AstraZeneca PLC (AZN) has a stake in this company. CEO has co-developed several drug which have been sold to Astra Zeneca, Megabits and MedImmune. Aridis Pharmaceuticals can be a potential buyout for AZN. Analyst Vernon Bernardino from H.C. Wainwright reiterated a buy rating and $19 price target on ARDS: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants and also binds to the omicron variant with no loss in affinity compared to the original Wuhan strain." Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class treatment! Cantor Fitzgerald also said last week that Aridis' pipeline is "underappreciated." ARDS Pan-Coronavirus Monoclonal Antibody Cocktail Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS , and the Common Cold Human Coronaviruses. It provides relevant drug levels for up to 1 year from prophylactic or therapeutic treatment. Market Cap of only 22.48Mil 52 Week Range 1.13 - 8.4
ALong
by TopgOptions
2
Euro falls to 4-mth low despite strong PMIsThe euro continues to head south in Wednesday trading. Currently, EUR/USD is trading at 1.1828, down 0.17% on the day. Just four weeks ago, EUR/USD was basking above the 122 level and looking strong against the US dollar. Fast forward to the present, and the euro is struggling to keep above the 1.18 level as its trades at its lowest level since November 23rd. It's been a dreadful March, with EUR/USD falling 2 percent this month. The main catalyst for the slide against the US dollar has been the significant rise in US Treasury yields, which have boosted the dollar. US 10-year yields rose to 1.73% on Friday, as shade below its 52-week high of 1.75%. If the upward trend resumes, we can expect the euro to lose more ground. Investor sentiment towards the eurozone has been weak, to such an extent that excellent PMI data on Wednesday failed to give the euro a much-needed boost. On the manufacturing front, France, Germany and the eurozone all showed strong growth, highlighted by an outstanding German read of 66.6. Services also showed improvement, although France and the eurozone remain in contraction territory. German Services PMI improved to 50.8, the first time the index has shown growth in seven months. The euro is also under pressure this week over a vaccine dispute with the EU. A shortage of AstraZeneca vaccines across Europe has resulted in a threat by the EU to block shipments of the vaccine to the UK. Such a move would likely send tense relations between the EU and the UK to a new low. The irony of the EU move to hoard vaccines has not been lost in British media, with The Telegraph newspaper publishing a survey which shows that a majority of people in Germany, France, Italy and Spain consider the AstraZeneca vaccine as unsafe. EUR has broken below critical support at 1.1840, where the 200-DMA is also situated. If EUR closes below this level, we can expect further losses, with the next support line at 1.1808. If the downturn continues, it could potentially reach as low as the 1.16 level in the coming days. On the upside, 1.1971 has some breathing room in resistance as EUR loses ground.
Editors' picks
by OANDA
19
PCI Biotech $PCIB bullish breaching 100EMA coming into Q4* Norwegian Drug Delivery Platform Biotech operating within the Oslo Cancer Cluster * Notoriously volatile norwegian small cap with large amount of stock held by enthusiastic retail investor crowd. * Ongoing research collaboration with AstraZeneca recently concluded, longs betting on partnership deal incoming. * Stock typically rallies ahead of quarterly reports and experiences sell the news events. * Norwegian biotech flying at All Time High valuations after recent Vaccibody partnership with Genentech.
OSL:PCIBLong
by savepiginvest